Topline results from the Phase III DESTINY-Breast11 trial show that Enhertu (trastuzumab deruxtecan) followed by paclitaxel, ...

JNJ-1900 (NBTXR3), a novel, potentially first-in-class oncology therapy, demonstrated a median overall survival of 23 months ...

A Phase III randomized trial published in JAMA Network Open found no significant difference in symptom improvement between ...

At the risk of stating the obvious, when evaluating a new EDC, step one is ensuring the EDC is in fact better. EDC technology ...

New long-term extension data from the Phase IIb/III QUASAR trial demonstrate that Tremfya (guselkumab) maintains durable ...

In this video interview, C.K. Wang, MD, chief medical officer, COTA, touches on how he would like to see greater industry ...

The single-inhaler demonstrated a meaningful improvement in lung function in the Phase III KALOS and LOGOS studies.

Imagine what we could do if we could take that time and replace it with a single login to a centralized, one stop shop system ...

Phase III trial data published in The New England Journal of Medicine support Nucala’s role as an add-on biologic therapy to ...

An article published by the Journal of the American Medical Association highlights recent updates made to the CONSORT ...

In this video interview, C.K. Wang, MD, chief medical officer, COTA, highlights cost and treatment sequencing as some of ...

Interim results from the Phase III ESSENCE trial published in The New England Journal of Medicine show once-weekly ...